Skip to content
  1. Home
  2. Supplements
  3. Inositol

Inositol

A sugar alcohol studied mainly for metabolic and reproductive outcomes in PCOS.

Supplements

Longevity Sexual health

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Inositol

A sugar alcohol studied mainly for metabolic and reproductive outcomes in PCOS.

Evidence category: Systematic review. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Inositol is a naturally occurring sugar alcohol involved in cell signaling, available in dietary and supplement forms as myo-inositol and D-chiro-inositol. It has been most studied in women with polycystic ovary syndrome, where randomized trials have examined effects on insulin sensitivity, hormone levels, and ovulation. A systematic review commissioned for international PCOS treatment guidelines found some metabolic and reproductive signals but concluded the overall evidence base remains limited and inconclusive.

Benefits reported in the imported source

  • Some randomized trials suggest inositol may improve insulin-related metabolic markers in women with polycystic ovary syndrome
  • Appears better tolerated on the digestive system than metformin in head-to-head trials

Risks and limits

  • The evidence-review panel behind the 2023 international PCOS guidelines rated the overall evidence as limited and inconclusive
  • Most research is in women with polycystic ovary syndrome, so benefits in other populations are not established

Source bottom line: Inositol shows some promising signals for metabolic and reproductive outcomes in polycystic ovary syndrome, but the guideline-informing systematic review found the evidence too limited to draw firm conclusions.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Thirty randomized controlled trials, 2230 women with polycystic ovary syndrome, with nineteen trials pooled in meta-analyses

Reported regimen
Trials of myo-inositol or D-chiro-inositol, alone or combined with other therapies, compared against placebo, metformin, or each other, across the pooled evidence base
Duration
Duration varied across the thirty pooled trials
Reported outcome
Some evidence of benefit for select metabolic measures and for D-chiro-inositol on ovulation, but the authors judged evidence for most outcomes limited and inconclusive, with myo-inositol causing fewer gastrointestinal side effects than metformin
Source
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines - PubMed
Claim provenance

evidence.json#/catalog:supplement:inositol/protocols/0

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Historical research outcome: no-verified-description · 2026-10-06

No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.

Pharmacokinetic context

No half-life recorded in this source snapshot. No value has been inferred.

Source references

Snapshot provenance

Source ID: catalog:supplement:inositol. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.

Related entries and components

None listed.